# B3B Migration Execution Record

- Issues: [#1057](https://github.com/mirichard/pm-tools-templates/issues/1057) (parent [#711](https://github.com/mirichard/pm-tools-templates/issues/711))
- Batch: `B3B`
- Source batch: `3`
- Asset count: `11`
- Primary domain: `Delivery`
- Rollback owner: `mirichard`
- Pre-batch SHA: `6b270df6e533f2f2c69fab37cecdc5c2b0ca01c1`
- Physical migration commit: `08b0a2231064a9176b390a26fd9885a7f64f4945`
- Manifest: `meta/migration-waves/b3b.json`
- Status: **PASS — physical migration and executed-state validation complete; integration pending**

## Scope decision

B3B is the next dependency-safe Batch 3 / Delivery wave after B3A. The planner selected an 11-asset SCC-safe atomic set under the 12-asset target/limit. Same-wave dependency cycles are retained intact; no dependency cycle is split.

## Assets and immutable hashes

| Legacy source | Canonical destination | Pre-move SHA-256 |
|---|---|---|
| `industry-specializations/healthcare-pharmaceutical/validation/cleaning_validation_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/cleaning_validation_protocol_template.md` | `78d19f4f25ccd2cf924fb577125d85f9866975882cf35df3525b7f67271f86d6` |
| `industry-specializations/healthcare-pharmaceutical/validation/performance_qualification_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/performance_qualification_protocol_template.md` | `0804914d1039f48703eb7cb79e17830dc2116b479544604b95f2d0822b11ec05` |
| `industry-specializations/information-technology/service-management/problem_management_process_template.md` | `domains/delivery/industry-specializations/information-technology/service-management/problem_management_process_template.md` | `b1ce59a97f16087acdc55f8b043d6a2ee7bfe002dd991a96b0de5a83e4001e85` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/compliance_risk_assessment_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/compliance_risk_assessment_template.md` | `3bf28881e9e6cc38e2993f59658dff595fe57d3e6e18da2a873ad0409aa494d5` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/health_authority_communication_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/health_authority_communication_plan_template.md` | `643053a540a351276fde3941240ccd4a3ee22eec7ca68cd9eb22f4e6498d0747` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_inspection_readiness_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_inspection_readiness_plan_template.md` | `31ae486a00b0a8c8b9552492d0bf9e549e1433a7943e9562aa5a35a4e07f893f` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/process_validation_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/process_validation_protocol_template.md` | `187d3224c4f0352fc2b447211c89168e43cdba82754902defa986086048a0c58` |
| `industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_strategy_plan_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/regulatory/regulatory_strategy_plan_template.md` | `8fab37973f6e648d612016fc8e58c925065ae3320c0ac03a346c059b43f8676b` |
| `industry-specializations/healthcare-pharmaceutical/validation/software_requirements_specification_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/software_requirements_specification_template.md` | `7a355d601468185b3611d8435128cf4663b4a519c4c94bcc979afe0c8d226e04` |
| `industry-specializations/healthcare-pharmaceutical/validation/installation_qualification_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/installation_qualification_protocol_template.md` | `9144caa3a3a6fcdc6c8aff2e5d9619a8d002637f25a6f994f07d7f2e526bce4c` |
| `industry-specializations/healthcare-pharmaceutical/validation/operational_qualification_protocol_template.md` | `domains/delivery/industry-specializations/healthcare-pharmaceutical/validation/operational_qualification_protocol_template.md` | `5c7ab97179ecb2f4112dd9be78841ae0fd800ac4f1efad80df4af9907e395687` |

## Checkpoint A — entry baseline

- Production `main` anchor: `6b270df6e533f2f2c69fab37cecdc5c2b0ca01c1`.
- Entry manifest: PASS — 11 assets, limit 12.
- Entry source/action guard: PASS — 11/11 planned sources; zero B3B execution records before move.
- Destination collision guard: PASS — zero pre-existing destinations.
- Source hash guard: PASS — 11/11 immutable hashes matched before move.

## Checkpoints B/C — canonical moves and compatibility

Physical migration commit: `08b0a2231064a9176b390a26fd9885a7f64f4945`.

Guarded execution run `34627766021` completed successfully.

- 11/11 canonical destination bodies match their immutable pre-move SHA-256 values.
- 11/11 legacy source paths are navigation-only pointers.
- 11/11 legacy pointers resolve to the intended Delivery canonical.
- Canonical bodies were copied byte-for-byte; inherited Markdown hard-break whitespace was intentionally preserved.

## Checkpoint D — canonical references and execution metadata

- 11/11 inventory moves are `executed-move-with-legacy-pointer` with B3B execution metadata.
- Exactly one B3B `batch_execution_records` entry exists.
- Canonical paths were updated in the current template index, template wrappers, decision-engine references, domain mapping, cross-reference mapping, value-flow mapping, and template catalog.
- Each migrated canonical catalog entry retains its legacy source in `alternate_paths`; related-template references were canonicalized without introducing nested compatibility aliases.
- Historical source identity remains preserved in the migration inventory.

## Checkpoint E — executed-state validation

Successful guarded execution validation: GitHub Actions run `34627766021`.

- Executed manifest: PASS — 11 assets.
- Migration-wave tests: PASS — 15/15.
- Migration-link checker tests: PASS — 5/5.
- Curated templates: PASS — 139 templates.
- Canonical paths: PASS — 0 errors; 1 inherited Stakeholder Register `path`/`canonical_path` warning.
- Destination hashes: PASS — 11/11.
- Legacy pointers: PASS — 11/11.
- Catalog compatibility paths: PASS — 11/11.
- Inventory execution records: PASS — 11/11.
- B3B batch execution records: PASS — exactly one.

The commit gate excludes only the 11 immutable canonical destination bodies from `git diff --check`, because those byte-preserved bodies contain inherited Markdown hard-break trailing spaces. All other staged B3B changes remain subject to the whitespace gate.

## Checkpoint F — integration/visual validation

**Pending.** Required branch/PR integration workflows and comprehensive visual regression must be reviewed on the final delivery head. Visual baselines must not be updated merely to force a green result.

## Checkpoint G — post-merge verification

**Pending.** After manual integration, production `main` must reverify the 11 canonical hashes, 11 legacy pointers, catalog compatibility, required workflows, comprehensive visual regression, and rollback anchor before B3B is treated as integrated and the next dependency-aware wave becomes authoritative.

## Technical-debt disposition

B3B is a structural migration. Canonical template bodies remain immutable; inherited content-quality issues are not silently repaired as part of this wave.

## Rollback

Pre-batch rollback anchor:

`6b270df6e533f2f2c69fab37cecdc5c2b0ca01c1`

After manual integration, the wave-level rollback method is:

`git revert <B3B-merge-sha>`
